难治性支原体肺炎应用小剂量糖皮质激素联合普米克吸入治疗的临床研究

Clinical Research on Low-Dose Glucocorticoid Combined with Pulmicort Inhalation Therapy in Refractory Mycoplasma Pneumonia

目的探讨难治性支原体肺炎应用小剂量糖皮质激素联合普米克吸入治疗的临床疗效。方法选取2014年6月至2015年6月于我院就诊的难治性支原体肺炎患者共86例,按治疗方法的不同将患者分为对照组和观察组,每组各43例。对照组患者采用基础治疗,观察组患者在此基础上采用小剂量糖皮质激素联合普米克吸入治疗。比较两组患者的治疗效果。结果观察组治疗总有效率为97.67%,显著高于对照组的74.42%,差异具有统计学意义(P<0.05)。观察组C-反应蛋白、红细胞沉降率、中性粒细胞等水平均明显低于对照组,差异具有统计学意义(P<0.05)。结论采用小剂量糖皮质激素联合普米克吸入治疗难治性支原体肺炎,可以有效改善患者的治疗效果,值得在临床上大力推广和应用。

Objective To investigate the clinical efficacy of low-dose glucocorticoid combined with pulmicort inhalation therapy in refractory mycoplasma pneumonia. Methods 86 patients with refractory mycoplasma pneumonia treated in our hospital from June 2014 to June 2015 were selected and divided into control group and observation group according to different treatment methods, with 43 cases in eachgroup. The control group was given basic treatment, the observation group was given low-dose glucocorticoid combined with pulmicort inhalation therapy on this basis. The treatment effects of two groups were compared. Results The total effective rate of observation group was 97.67%, significantly higher than 74.42% of control group, with statistically significant difference （P 〈0.05）. The C- reactive protein level, erythrocyte sedimentation rate and neutrophil level of observation group were significantly lower than those of control group, with statistically significant difference （P〈0.05）. Conclusions Low-dose glucocorticoid combined with pulmicort inhalation therapy in refractory mycoplasma pneumonia can effectively improve the treatment effect, which is worthy of promotion and application in clinic.